A study comparing the Resolute Onyx drug-eluting stent from Medtronic (NYSE:MDT) and the BioFreedom stent made by Biosensors International (PINK:BSNRY) showed the Medtronic device to be non-inferior in patients on a one-month dual anti-platelet therapy regimen, according to results presented yesterday at the annual Transcatheter Cardiovascular Technologies conference in San Francisco.
Medtronic launched the 2,000-patient study in August 2017. It’s designed to compare a one-month course of aspirin and an anti-coagulant in conjunction with the Resolute Onyx device or the BioFreedom stent. The zotorolimus-eluting Resolute Onyx is made from a single strand of cobalt alloy, formed into a sinusoidal wave with a radio-opaque core. The Biosensors device is a polymer-free drug-coated stent.